{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:49Z","timestamp":1781636089681,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immunotherapy is an attractive proposition for preventing the spread of pathologic tau in Alzheimer\u2019s disease and other tauopathies. Given that tau is heavily truncated in tauopathies, it is hypothesised that directly targeting the repeat domain which forms the core of pathological filaments will improve the likelihood of success. S1D12, a chimeric IgG2a isolated via phage display, recognises 2N4R tau341-353 with high affinity (200\u00a0pM) and has previously been shown to prevent tau aggregation and propagation in vitro. We further explored the pharmacokinetics and biodistribution of S1D12 as well as its efficacy in a tauopathy mouse model. We also verified its efficacy in vitro against tau seeding species from multiple human tauopathies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single dose S1D12 intraperitoneal injections (30\u00a0mg\/kg) were performed in wild-type mice followed by tissue harvest at multiple time points. For efficacy studies, four-weekly doses followed by four-fortnightly doses of S1D12 (30\u00a0mg\/kg) or negative control antibody were administered intraperitoneally to Line 66 tau transgenic mice. Two cohorts, beginning from 2\u00a0months and 4.5\u00a0months of age were utilised. Endpoints included quantification of aggregated tau, seed-competent tau and insoluble phosphorylated tau in brain homogenates, as well as neurofilament light (NfL), tau phosphorylated at Thr-217 (pTau217) and core tau in plasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      S1D12 was detected in plasma and in brain with a t\n                      <jats:sub>max<\/jats:sub>\n                      of 24\/48\u00a0h respectively, and a slow washout over 7\u00a0days (t\n                      <jats:sub>1\/2<\/jats:sub>\n                      \u2009&gt;\u2009230\u00a0h), with 0.35% CNS bioavailability. S1D12 inhibited the generation of aggregated tau, seed-competent tau and insoluble phosphorylated tau in transgenic mice. This was associated with a reduction in NfL and pTau217, and an increase in core tau in plasma. In the 4.5-month cohort, S1D12 did not remove already established tau aggregates below baseline. Additionally, S1D12 inhibited seeding tau species from different tauopathies to a similar degree, independent of structural diversity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>S1D12, a high-affinity antibody targeting the R4 repeat domain of tau offers potential for halting progression of tau pathology through inhibition of tau aggregation rather than removal of established aggregates. These findings support the notion that both early diagnosis and intervention are key for the treatment of AD and other tauopathies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-01985-x","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:44:14Z","timestamp":1771065854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing matters: early administration of a high-affinity antibody targeting the tau repeat domain prevents aggregation in a mouse tauopathy model"],"prefix":"10.1186","volume":"18","author":[{"given":"Lewis K.","family":"Penny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Arastoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lofthouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter I.","family":"Imoesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Shiells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Melis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude M.","family":"Wischik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Palliyil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"4","key":"1985_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.","journal-title":"Alzheimers Res Ther"},{"key":"1985_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","volume":"4","author":"J Cummings","year":"2018","unstructured":"Cummings J, Lee G, Ritter A, Zhong K. Alzheimer\u2019s disease drug development pipeline: 2018. Alzheimers Dement (N Y). 2018;4:195\u2013214.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"1985_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"1985_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"1985_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"key":"1985_CR6","doi-asserted-by":"publisher","first-page":"n1462","DOI":"10.1136\/bmj.n1462","volume":"373","author":"E Mahase","year":"2021","unstructured":"Mahase E. No title. FDA approves controversial Alzheimer\u2019s drug despite uncertainty over effectiveness. BMJ. 2021;373:n1462.","journal-title":"BMJ"},{"key":"1985_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.brainresbull.2022.10.006","volume":"190","author":"DR Thal","year":"2022","unstructured":"Thal DR, Tom\u00e9 SO. The central role of tau in Alzheimer\u2019s disease: from neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull. 2022;190:204\u201317.","journal-title":"Brain Res Bull"},{"issue":"S165","key":"1985_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-0404.1996.tb05866.x","volume":"94","author":"H Braak","year":"1996","unstructured":"Braak H, Braak E. Evolution of the neuropathology of Alzheimer\u2019s disease. Acta Neurol Scand. 1996;94(S165):3\u201312.","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"1985_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0002-9440(10)64573-7","volume":"157","author":"EB Mukaetova-Ladinska","year":"2000","unstructured":"Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Hills R, et al. Staging of cytoskeletal and \u03b2-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer\u2019s disease. Am J Pathol. 2000;157(2):623\u201336.","journal-title":"Am J Pathol"},{"issue":"8","key":"1985_CR10","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/cells12081184","volume":"12","author":"A Zabala-Findlay","year":"2023","unstructured":"Zabala-Findlay A, Penny LK, Lofthouse RA, Porter AJ, Palliyil S, Harrington CR, et al. Utility of blood-based tau biomarkers for mild cognitive impairment and Alzheimer\u2019s disease: systematic review and meta-analysis. Cells. 2023;12(8):1184.","journal-title":"Cells"},{"issue":"3","key":"1985_CR11","doi-asserted-by":"publisher","first-page":"e12792","DOI":"10.1111\/nan.12792","volume":"48","author":"GG Kovacs","year":"2022","unstructured":"Kovacs GG, Ghetti B, Goedert M. Classification of diseases with accumulation of Tau protein. Neuropathol Appl Neurobiol. 2022;48(3):e12792.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"1985_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41573-020-00217-7","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A. Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating. Nat Rev Drug Discov. 2021;20(1):3\u20136.","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"1985_CR13","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.3390\/ijms21228673","volume":"21","author":"M Arastoo","year":"2020","unstructured":"Arastoo M, Lofthouse R, Penny LK, Harrington CR, Porter A, Wischik CM, et al. Current progress and future directions for tau-based fluid biomarker diagnostics in Alzheimer\u2019s disease. Int J Mol Sci. 2020;21(22):8673.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1985_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0197-4580(95)97327-D","volume":"16","author":"CM Wischik","year":"1995","unstructured":"Wischik CM, Edwards PC, Lai RY, Gertz HN, Xuereb JH, Paykel ES, et al. Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer\u2019s disease. Neurobiol Aging. 1995;16(3):409\u201317.","journal-title":"Neurobiol Aging"},{"key":"1985_CR15","doi-asserted-by":"publisher","first-page":"e76494","DOI":"10.7554\/eLife.76494","volume":"11","author":"S L\u00f6vestam","year":"2022","unstructured":"L\u00f6vestam S, Koh FA, Van Knippenberg B, Kotecha A, Murzin AG, Goedert M, et al. Assembly of recombinant tau into filaments identical to those of Alzheimer\u2019s disease and chronic traumatic encephalopathy. Elife. 2022;11:e76494.","journal-title":"Elife"},{"issue":"12","key":"1985_CR16","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1073\/pnas.85.12.4506","volume":"85","author":"CM Wischik","year":"1988","unstructured":"Wischik CM, Nov\u00e1k M, Th\u00f8gersen HC, Edwards PC, Runswick MJ, Jakes R, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA. 1988;85(12):4506\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1985_CR17","doi-asserted-by":"publisher","first-page":"105120","DOI":"10.1016\/j.nbd.2020.105120","volume":"146","author":"R Sopko","year":"2020","unstructured":"Sopko R, Golonzhka O, Arndt J, Quan C, Czerkowicz J, Cameron A, et al. Characterization of tau binding by gosuranemab. Neurobiol Dis. 2020;146:105120.","journal-title":"Neurobiol Dis"},{"issue":"8","key":"1985_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","volume":"27","author":"T Dam","year":"2021","unstructured":"Dam T, Boxer AL, Golbe LI, H\u00f6glinger GU, Morris HR, Litvan I, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"1985_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13195-024-01561-1","volume":"16","author":"M Arastoo","year":"2024","unstructured":"Arastoo M, Penny LK, Lofthouse R, Abdallah A, Abrahamsson A, Marini P, et al. High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):209.","journal-title":"Alzheimers Res Ther"},{"key":"1985_CR20","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s00018-014-1804-z","volume":"72","author":"V Melis","year":"2015","unstructured":"Melis V, Zabke C, Stamer K, Magbagbeolu M, Schwab K, Marschall P, et al. Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer\u2019s disease and frontotemporal lobar degeneration. Cell Mol Life Sci. 2015;72:2199\u2013222.","journal-title":"Cell Mol Life Sci"},{"key":"1985_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/FBP.0000000000000133","volume":"26","author":"V Melis","year":"2015","unstructured":"Melis V, Magbagbeolu M, Rickard JE, Horsley D, Davidson K, Harrington KA, et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol. 2015;26:353\u201368.","journal-title":"Behav Pharmacol"},{"issue":"1","key":"1985_CR22","doi-asserted-by":"publisher","first-page":"fcaa033","DOI":"10.1093\/braincomms\/fcaa033","volume":"2","author":"AL Cranston","year":"2020","unstructured":"Cranston AL, Wysocka A, Steczkowska M, Zadro\u017cny M, Palasz E, Harrington CR, et al. Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer\u2019s disease and frontotemporal lobar degeneration. Brain Commun. 2020;2(1):fcaa033.","journal-title":"Brain Commun"},{"key":"1985_CR23","doi-asserted-by":"publisher","unstructured":"Lemke N, Melis V, Lauer D, Magbagbeolu M, Neumann B, Harrington CR, Riedel G, Wischik CM, Theuring F, Schwab K. Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia. J Biol Dyn. 2020;295(52):18508\u201323. https:\/\/doi.org\/10.1074\/jbc.RA120.014890.","DOI":"10.1074\/jbc.RA120.014890"},{"key":"1985_CR24","doi-asserted-by":"publisher","unstructured":"Schwab K, Melis V, Harrington CR, Wischik CM, Magbagbeolu M, Theuring F, Riedel G. Proteomic analysis of hydromethylthionine in the line 66 model of frontotemporal dementia demonstrates actions on tau-dependent and tau-independent networks. Cells. 2021;10(8):2162. https:\/\/doi.org\/10.3390\/cells10082162.","DOI":"10.3390\/cells10082162"},{"key":"1985_CR25","doi-asserted-by":"publisher","unstructured":"DuSert NP, Hurst V, Ahmed SB, Bailoo JD, Bannach-Brown A, Blainey P, Brookes AJ, Bruford EA, Churchill GA, Clarke M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. https:\/\/doi.org\/10.1371\/journal.pbio.3000410.","DOI":"10.1371\/journal.pbio.3000410"},{"issue":"3","key":"1985_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306\u201314.","journal-title":"Comput Methods Programs Biomed"},{"key":"1985_CR27","doi-asserted-by":"crossref","unstructured":"Perez M, Cuadros R, Medina M. Tau assembly into filaments.\u00a0In: Amyloid proteins: methods and protocols. 2018. p. 447\u2013461.","DOI":"10.1007\/978-1-4939-7816-8_27"},{"key":"1985_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-0716-3629-9_5","volume":"2754","author":"D Horsley","year":"2024","unstructured":"Horsley D, Rickard JE, Vorley T, Leeper MF, Wischik CM, Harrington CR. Assays for the screening and characterization of tau aggregation inhibitors. Tau Protein Methods Protoc. 2024;2754:93\u2013104.","journal-title":"Tau Protein Methods Protoc"},{"issue":"41","key":"1985_CR29","doi-asserted-by":"publisher","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","volume":"111","author":"BB Holmes","year":"2014","unstructured":"Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A. 2014;111(41):E4376\u201385.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1985_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):22\u201335.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1985_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13024-017-0172-1","volume":"12","author":"MG Agadjanyan","year":"2017","unstructured":"Agadjanyan MG, Zagorski K, Petrushina I, Davtyan H, Kazarian K, Antonenko M, et al. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. Mol Neurodegener. 2017;12(1):33.","journal-title":"Mol Neurodegener"},{"key":"1985_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-020-00404-5","volume":"15","author":"GS Gibbons","year":"2020","unstructured":"Gibbons GS, Kim S, Wu Q, Riddle DM, Leight SN, Changolkar L, et al. Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer\u2019s disease. Mol Neurodegener. 2020;15:64.","journal-title":"Mol Neurodegener"},{"key":"1985_CR33","doi-asserted-by":"crossref","unstructured":"Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. In: MAbs\u00a02013. USA: Taylor & Francis; 2013. p. 297\u2013305.","DOI":"10.4161\/mabs.23684"},{"issue":"1","key":"1985_CR34","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.xphs.2020.05.025","volume":"110","author":"H Chang","year":"2021","unstructured":"Chang H, Kim SJ, Shah DK. Whole-body pharmacokinetics of antibody in mice determined using enzyme-linked immunosorbent assay and derivation of tissue interstitial concentrations. J Pharm Sci. 2021;110(1):446\u201357.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1985_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/JAD-2012-121354","volume":"33","author":"SK Forest","year":"2013","unstructured":"Forest SK, Acker CM, D\u2019Abramo C, Davies P. Methods for measuring tau pathology in transgenic mouse models. J Alzheimers Dis. 2013;33(2):463\u201371.","journal-title":"J Alzheimers Dis"},{"issue":"23","key":"1985_CR36","doi-asserted-by":"publisher","first-page":"19440","DOI":"10.1074\/jbc.M112.346072","volume":"287","author":"N Kfoury","year":"2012","unstructured":"Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem. 2012;287(23):19440\u201351.","journal-title":"J Biol Chem"},{"issue":"374","key":"1985_CR37","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL Devos","year":"2017","unstructured":"Devos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1985_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/jnr.490390607","volume":"39","author":"L Otvos Jr","year":"1994","unstructured":"Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 1994;39(6):669\u201373.","journal-title":"J Neurosci Res"},{"issue":"3","key":"1985_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0304-3940(95)11484-E","volume":"189","author":"M Goedert","year":"1995","unstructured":"Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189(3):167\u201370.","journal-title":"Neurosci Lett"},{"issue":"3","key":"1985_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81(3):255\u201363.","journal-title":"JAMA Neurol"},{"issue":"8","key":"1985_CR41","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381.","journal-title":"JAMA"},{"issue":"9","key":"1985_CR42","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739\u201352.","journal-title":"Lancet Neurol"},{"key":"1985_CR43","doi-asserted-by":"publisher","unstructured":"Goedert M, Crowther RA, Scheres SHW, Spillantini MG. Tau and neurodegeneration. Cytoskeleton. 2024;81(3):95\u2013102. https:\/\/doi.org\/10.1002\/cm.21812.","DOI":"10.1002\/cm.21812"},{"key":"1985_CR44","doi-asserted-by":"publisher","unstructured":"Iqbal K, Liu F, Gong CX, Alonso A.delC, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009;118(1):53\u201369. https:\/\/doi.org\/10.1007\/s00401-009-0486-3.","DOI":"10.1007\/s00401-009-0486-3"},{"issue":"10","key":"1985_CR45","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1073\/pnas.84.10.3472","volume":"84","author":"PN Hoffman","year":"1987","unstructured":"Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price D. Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci. 1987;84(10):3472\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1985_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0006-8993(03)03219-0","volume":"987","author":"N Norgren","year":"2003","unstructured":"Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003;987(1):25\u201331.","journal-title":"Brain Res"},{"issue":"10","key":"1985_CR47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577\u201389.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1985_CR48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383.","journal-title":"Nat Med"},{"issue":"5","key":"1985_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557\u201366.","journal-title":"JAMA Neurol"},{"key":"1985_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.sbi.2020.05.011","volume":"64","author":"SHW Scheres","year":"2020","unstructured":"Scheres SHW, Zhang W, Falcon B, Goedert M. Cryo-EM structures of tau filaments. Curr Opin Struct Biol. 2020;64:17\u201325.","journal-title":"Curr Opin Struct Biol"},{"issue":"11","key":"1985_CR51","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/pro.3499","volume":"27","author":"G Ghag","year":"2018","unstructured":"Ghag G, Bhatt N, Cantu DV, Guerrero\u2010Munoz MJ, Ellsworth A, Sengupta U, et al. Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross\u2010seeding behavior. Protein Sci. 2018;27(11):1901\u20139.","journal-title":"Protein Sci"},{"issue":"1","key":"1985_CR52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/life11010028","volume":"11","author":"G Niewiadomska","year":"2021","unstructured":"Niewiadomska G, Niewiadomski W, Steczkowska M, Gasiorowska A. Tau oligomers neurotoxicity. Life. 2021;11(1):28.","journal-title":"Life"},{"issue":"14","key":"1985_CR53","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.neuron.2023.04.020","volume":"111","author":"M Colom-Cadena","year":"2023","unstructured":"Colom-Cadena M, Davies C, Sirisi S, Lee J, Simzer EM, Tzioras M, et al. Synaptic oligomeric tau in Alzheimer\u2019s disease\u2014a potential culprit in the spread of tau pathology through the brain. Neuron. 2023;111(14):2170-2183.e6.","journal-title":"Neuron"},{"issue":"11","key":"1985_CR54","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/jamaneurol.2023.3530","volume":"80","author":"RN Taddei","year":"2023","unstructured":"Taddei RN, Perbet R, De Gerando AM, Wiedmer AE, Sanchez-Mico M, Stewart TC, et al. Tau oligomer\u2013containing synapse elimination by microglia and astrocytes in Alzheimer disease. JAMA Neurol. 2023;80(11):1209\u201321.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1985_CR55","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TL, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med. 2020;26(3):398\u2013407.","journal-title":"Nat Med"},{"issue":"4","key":"1985_CR56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"593","key":"1985_CR57","doi-asserted-by":"publisher","first-page":"eabb2639","DOI":"10.1126\/scitranslmed.abb2639","volume":"13","author":"G Ayalon","year":"2021","unstructured":"Ayalon G, Lee S, Adolfsson O, Foo-Atkins C, Atwal JK, Blendstrup M, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer\u2019s disease. Sci Transl Med. 2021;13(593):eabb2639.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1985_CR58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","volume":"8","author":"M Roberts","year":"2020","unstructured":"Roberts M, Sevastou I, Imaizumi Y, Mistry K, Talma S, Dey M, et al. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer\u2019s disease. Acta Neuropathol Commun. 2020;8(1):13.","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"1985_CR59","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/acn3.176","volume":"2","author":"K Yanamandra","year":"2015","unstructured":"Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2(3):278\u201388.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1985_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40035-024-00417-w","volume":"13","author":"LK Penny","year":"2024","unstructured":"Penny LK, Lofthouse R, Arastoo M, Porter A, Palliyil S, Harrington CR, et al. Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer\u2019s disease. Transl Neurodegener. 2024;13(1):25.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"1985_CR61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JAD-231034","volume":"97","author":"A Anschuetz","year":"2024","unstructured":"Anschuetz A, Schwab K, Harrington CR, Wischik CM, Riedel G. A meta-analysis on presynaptic changes in Alzheimer\u2019s disease. J Alzheimers Dis. 2024;97(1):145\u201362. https:\/\/doi.org\/10.3233\/JAD-231034.","journal-title":"J Alzheimers Dis"},{"key":"1985_CR62","doi-asserted-by":"publisher","unstructured":"Anschuetz A, Schwab K, Harrington CR, Wischik CM, Riedel G. Proteomic and non-proteomic changes of presynaptic proteins in animal models of Alzheimer\u2019s disease: a meta-analysis 2015-2023. J Alzheimers Dis. 2025. In press. https:\/\/doi.org\/10.1177\/13872877251362212.","DOI":"10.1177\/13872877251362212"},{"issue":"3","key":"1985_CR63","doi-asserted-by":"publisher","first-page":"fcad113","DOI":"10.1093\/braincomms\/fcad113","volume":"5","author":"TS Saunders","year":"2023","unstructured":"Saunders TS, Pozzolo FE, Heslegrave A, King D, Mcgeachan RI, Spires-Jones MP, et al. Predictive blood biomarkers and brain changes associated with age-related cognitive decline. Brain Commun. 2023;5(3):fcad113.","journal-title":"Brain Commun"},{"issue":"3","key":"1985_CR64","doi-asserted-by":"publisher","first-page":"fcad142","DOI":"10.1093\/braincomms\/fcad142","volume":"5","author":"CA Saura","year":"2023","unstructured":"Saura CA, Parra-Damas A. Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer\u2019s disease? Brain Commun. 2023;5(3):fcad142.","journal-title":"Brain Commun"},{"key":"1985_CR65","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","volume":"598","author":"Y Shi","year":"2021","unstructured":"Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, et al. Structure-based classification of tauopathies. Nature. 2021;598:359\u201363.","journal-title":"Nature"},{"issue":"4","key":"1985_CR66","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3233\/JAD-131843","volume":"37","author":"I Morales","year":"2013","unstructured":"Morales I, Jim\u00e9nez JM, Mancilla M, Maccioni RB. Tau oligomers and fibrils induce activation of microglial cells. J Alzheimers Dis. 2013;37(4):849\u201356.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"1985_CR67","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","volume":"16","author":"S Lee","year":"2016","unstructured":"Lee S, Le Pichon CE, Adolfsson O, Gafner V, Pihlgren M, Lin H, et al. Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Rep. 2016;16(6):1690\u2013700.","journal-title":"Cell Rep"},{"key":"1985_CR68","doi-asserted-by":"crossref","unstructured":"Congdon EE, Pan R, Jiang Y, Sandusky-Beltran LA, Dodge A, Lin Y, Liu M, Kuo M, Kong X, Sigurdsson EM. Single domain antibodies targeting pathological tau protein: influence of four IgG subclasses on efficacy and toxicity.\u00a0eBioMedicine. 2022;84:104249.","DOI":"10.1016\/j.ebiom.2022.104249"},{"key":"1985_CR69","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40478-020-00948-z","volume":"8","author":"M Zilkova","year":"2020","unstructured":"Zilkova M, Nolle A, Kovacech B, Kontsekova E, Weisova P, Filipcik P, et al. Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation. Acta Neuropathol Commun. 2020;8:74.","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"1985_CR70","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/00005072-199906000-00011","volume":"58","author":"O Bugiani","year":"1999","unstructured":"Bugiani O, Murrell JR, Giaccone G, Hasegawa M, Ghigo G, Tabaton M, et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol. 1999;58(6):667\u201377.","journal-title":"J Neuropathol Exp Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-01985-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-01985-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-01985-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:16:28Z","timestamp":1781633788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-01985-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1985"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-01985-x","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experiments were carried out in accordance with the European Communities Council Directive (63\/2010\/EU) and a project license with local ethical approval under the UK Animals (Scientific Procedures) Act (1986).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}